- Ironwood Pharmaceuticals (IRWD, Financial) will present significant findings related to short bowel syndrome (SBS) and irritable bowel syndrome with constipation (IBS-C) at Digestive Disease Week 2025.
- The company highlights adoption of newly approved ICD-10 codes for SBS and results from a Phase III study on linaclotide in pediatric IBS-C patients.
- Presentations to occur from May 3-6, 2025 in San Diego, covering real-world data and clinical research insights.
Ironwood Pharmaceuticals, Inc. (IRWD), a biotechnology leader in gastrointestinal and rare diseases therapies, is set to present pivotal real-world data at the upcoming Digestive Disease Week® (DDW) 2025, held in San Diego from May 3-6. The company will focus on the utilization and impact of recently approved ICD-10 codes specific to short bowel syndrome (SBS) patients requiring parenteral support.
The ICD-10 codes received approval from the Centers for Medicare and Medicaid Services in October 2023, enhancing disease recognition and patient care tracking. This development aligns with Ironwood's progress on apraglutide, a synthetic GLP-2 analog for SBS patients. "The adoption of these codes is crucial for rare diseases like SBS," stated Dr. Michael Shetzline, Ironwood's Chief Medical Officer.
Concurrently, Ironwood is showcasing the first Phase III study results of linaclotide in pediatric patients with irritable bowel syndrome with constipation (IBS-C), covering ages 7-17. This study, pivotal for expanding treatment options in this age group, complements their analysis on pediatric functional constipation transitioning to chronic idiopathic constipation in young adults.
These presentations underscore Ironwood's commitment to advancing care for gastrointestinal conditions, as evidenced by their leading product LINZESS® (linaclotide), marketed for both IBS-C and chronic idiopathic constipation (CIC). LINZESS, co-developed with AbbVie in the United States, accentuates Ironwood's innovative footprint in therapeutic development and commercialization.
